Alleviating sepsis: Revealing the protective role of costunolide in a cecal ligation and puncture rat model.

Cecal ligation and puncture Costunolide Oxidative stress Rat Sepsis

Journal

Iranian journal of basic medical sciences
ISSN: 2008-3866
Titre abrégé: Iran J Basic Med Sci
Pays: Iran
ID NLM: 101517966

Informations de publication

Date de publication:
2024
Historique:
received: 05 10 2023
accepted: 13 11 2023
medline: 17 4 2024
pubmed: 17 4 2024
entrez: 17 4 2024
Statut: ppublish

Résumé

Sepsis poses a significant threat to human life, rendering it a burdensome medical disease. Despite significant advancements, the current state of medical science still lacks a viable and efficacious cure. Costunolide (COST) is a multifaceted sesquiterpene lactone that exhibits a range of actions, including anti-inflammatory and antioxidant properties. We investigated the potential impacts of COST on a rat sepsis model caused by cecal ligation and puncture (CLP). We created an experimental rat model with the following groups: SHAM, CLP, CLP+low dose COST, and CLP+high dose COST. Blood, kidney, and lung samples were collected. Inflammatory mediators such as interleukin-1beta (IL-1β), IL-6, tumor necrosis factor-alpha (TNF- α), and nuclear factor kappa-B (NF-κB) were investigated. In addition, we assessed oxidative stress by measuring 8-Hydroxydeoxyguanosine (8-OHdG) immunopositivity, MDA levels, glutathione (GSH), and superoxide dismutase (SOD) activity. Histopathological and immunohistochemical examinations backed up our findings. Compared to the CLP group, the COST group showed a reduction in inflammatory and oxidative stress indicators. The expression of inflammatory mediators was suppressed by COST, and histological examinations revealed improvements in kidney and lung tissues in the treatment groups. Our study highlights the preventive effects of COST against CLP-induced sepsis-related injury. Considering its beneficial effects against many diseases, COST is worthy as to be evaluated against sepsis.

Identifiants

pubmed: 38629103
doi: 10.22038/IJBMS.2024.75372.16335
pmc: PMC11017843
doi:

Types de publication

Journal Article

Langues

eng

Pagination

567-576

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Auteurs

Mustafa Can Güler (MC)

Department of Physiology, Faculty of Medicine, Atatürk University, Erzurum, Turkey.

Ayhan Tanyeli (A)

Department of Physiology, Faculty of Medicine, Atatürk University, Erzurum, Turkey.

Ersen Eraslan (E)

Department of Physiology, Faculty of Medicine, Bandırma OnYedi Eylül University, Balıkesir, Turkey.

Özgür Çelebi (Ö)

Department of Medical Microbiology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.

Demet Çelebi (D)

Department of Microbiology, Faculty of Veterinary Medicine, Ataturk University, Erzurum, Turkey.
Ataturk University Vaccine Application and Development Center, Ataturk University, Erzurum, Turkey.

Selim Çomakli (S)

Department of Pathology, Faculty of Veterinary, Atatürk University, Erzurum, Turkey.

Emir Enis Yurdgülü (EE)

Department of Biochemistry, Faculty of Pharmacy, Atatürk University, Erzurum, Turkey.

Yasin Bayir (Y)

Department of Biochemistry, Faculty of Pharmacy, Atatürk University, Erzurum, Turkey.

Classifications MeSH